Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Furthering cell therapy ambition across oncology and autoimmune diseases
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
Subscribe To Our Newsletter & Stay Updated
